AU2002242203B2 - (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors - Google Patents

(2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors Download PDF

Info

Publication number
AU2002242203B2
AU2002242203B2 AU2002242203A AU2002242203A AU2002242203B2 AU 2002242203 B2 AU2002242203 B2 AU 2002242203B2 AU 2002242203 A AU2002242203 A AU 2002242203A AU 2002242203 A AU2002242203 A AU 2002242203A AU 2002242203 B2 AU2002242203 B2 AU 2002242203B2
Authority
AU
Australia
Prior art keywords
compound
accordance
methyl
bond
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002242203A
Other languages
English (en)
Other versions
AU2002242203A1 (en
Inventor
Ken Chow
Wenkui Ken Fang
Michael E. Garst
Daniel W. Gil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2002242203A1 publication Critical patent/AU2002242203A1/en
Application granted granted Critical
Publication of AU2002242203B2 publication Critical patent/AU2002242203B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/08—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/14—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002242203A 2001-02-27 2002-02-19 (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors Ceased AU2002242203B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/794,874 US6534542B2 (en) 2001-02-27 2001-02-27 (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US09/794,874 2001-02-27
PCT/US2002/005021 WO2002068384A2 (en) 2001-02-27 2002-02-19 (2-hydroxy)ethyl-thioureas useful as modulators of alpha2b adrenergic receptors

Publications (2)

Publication Number Publication Date
AU2002242203A1 AU2002242203A1 (en) 2003-03-06
AU2002242203B2 true AU2002242203B2 (en) 2007-01-18

Family

ID=25163943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002242203A Ceased AU2002242203B2 (en) 2001-02-27 2002-02-19 (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors

Country Status (6)

Country Link
US (1) US6534542B2 (enExample)
EP (1) EP1381593A2 (enExample)
JP (1) JP4159363B2 (enExample)
AU (1) AU2002242203B2 (enExample)
CA (1) CA2439838C (enExample)
WO (1) WO2002068384A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6699493B2 (en) * 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US7358269B2 (en) * 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) * 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) * 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
KR20070063016A (ko) * 2004-09-24 2007-06-18 알러간, 인코포레이티드 알파2 아드레날린성 아고니스트로서 작용하는 4-(축합시클릭메틸)-이미다졸-2-티온
WO2006036507A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008014299A2 (en) * 2006-07-27 2008-01-31 Allergan, Inc. Use of an alpha2-agonist composition for the treatment of hyperlipidemia
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
AU2007337097A1 (en) 2006-12-22 2008-07-03 Allergan, Inc. Alpha-2B adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US8455548B2 (en) * 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2009052075A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
WO2009052072A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US20120190719A1 (en) 2009-08-26 2012-07-26 Allergan, Inc. Methods of treating motor disorders with alpha-2b andrenergic receptor agonists
KR101847669B1 (ko) 2010-08-16 2018-05-24 알러간, 인코포레이티드 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
EP3004119B1 (en) * 2013-06-04 2019-01-16 Silatronix, Inc. Nitrile-substituted silanes and electrolyte compositions and electrochemical devices containing them
WO2015037665A1 (ja) 2013-09-12 2015-03-19 信越化学工業株式会社 β－シクロラバンジュラール及びその誘導体の製造方法
US20160221923A1 (en) * 2013-09-12 2016-08-04 Shin-Etsu Chemical Co., Ltd. Method for producing cyclolavandulol and derivative thereof
RU2552529C1 (ru) * 2013-11-29 2015-06-10 Федеральное государственное бюджетное учреждение "Медицинский радиологический научный центр" Министерства здравоохранения Российской Федерации (ФГБУ МРНЦ Минздрава России) Вазопрессорное средство
US11725139B2 (en) 2021-12-13 2023-08-15 Saudi Arabian Oil Company Manipulating hydrophilicity of conventional dye molecules for water tracer applications
US12631612B2 (en) 2021-12-13 2026-05-19 Saudi Arabian Oil Company Fluorescent dye molecules for tracer applications in subterranean formations
US12440821B2 (en) 2021-12-13 2025-10-14 Saudi Arabian Oil Company Method for tracing subterranean formations with oil-soluble organic molecular tracers and extracting them of from oil phases
US12188350B2 (en) * 2022-06-08 2025-01-07 Saudi Arabian Oil Company Fluorescent dye oil tracer compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2161772A (en) * 1936-04-17 1939-06-06 Monsanto Chemicals Phenol stabilization
US3686303A (en) * 1967-04-20 1972-08-22 Du Pont Certain substituted cyclohexyl ureas and thioureas
SU795462A3 (ru) 1975-03-14 1981-01-07 Эдьт Дьедьесерведьесети Дьяр (Фирма) Способ получени тиокарбамидныхпРОизВОдНыХ
US5212176A (en) 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
TWI283669B (en) 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Org Chem vol 48(4) 1983, pp 507-512 *

Also Published As

Publication number Publication date
WO2002068384A3 (en) 2003-03-06
JP4159363B2 (ja) 2008-10-01
EP1381593A2 (en) 2004-01-21
US20020161051A1 (en) 2002-10-31
CA2439838A1 (en) 2002-09-06
US6534542B2 (en) 2003-03-18
CA2439838C (en) 2012-01-24
WO2002068384A2 (en) 2002-09-06
JP2004524312A (ja) 2004-08-12

Similar Documents

Publication Publication Date Title
US6534542B2 (en) (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
AU2002242203A1 (en) (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors
EP1280524B1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
EP1280525B1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
US20040220402A1 (en) 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
CZ239794A3 (en) Phenyl derivatives and pharmaceutical compositions containing thereof
AU2001253383A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
CA2521883C (en) Indene derivatives as pharmaceutical agents
WO2003035178A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
DE69510553T2 (de) Isothioharnstoff-derivate als no synthase hemmer
DE2724948A1 (de) Hydantoinderivate, verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zubereitungen
NZ553290A (en) 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
US8178571B2 (en) Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
NZ553341A (en) 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
RU2491278C2 (ru) Гетероциклические производные индана, используемые для снятия боли и лечения состояний, подобных глаукоме
EP0284202A1 (en) Substituted hydantoin compounds
EP0461012B1 (fr) Dérivés de (1-phénylpyrrolidin-2-yl)méthylpipérazine, leur préparation et leur application en thérapeutique
DE69315474T2 (de) Neue Alkencarbonsäurederivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
EP0581003A1 (de) Imidazolyl-substituierte Cyclohexanderivate
DE69411747T2 (de) Phosphinsäure-derivate mit anti-hyperglyzemie und/oder anti-fettsucht wirkung
EP0294292A2 (fr) Dérivé de l'acide benzo [B] thiophène - 7 carboxylique, son procédé de préparation et les compositions pharmaceutiques qui le contiennent
DE3735641A1 (de) (+)-1-isopropylamino-3-(o-(pyrrol-1-yl) -phenoxy)-propanol, verfahren zu seiner herstellung sowie pharmazeutische praeparate und deren verwendung
HK1051324B (en) Methods and compositions for modulating alpha adrenergic receptor activity
HK1051005B (en) Methods and compositions for modulating alpha adrenergic receptor activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired